By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem’s new website goes live
Bubendorf, Switzerland: – Peptide and oligonucleotide leading manufacturer Bachem AG has rolled out a redesigned and re-engineered online presence with its new website going ‘live’ from March 2021.
The new website design and updated content at www.bachem.com emphasizes interactivity, accessibility, and more intuitive navigation to enable faster access to information on Bachem’s products and services for customers and visitors. It also allows them to contact Bachem more easily.
Website redesign objectives
The primary aim driving Bachem’s website project was to provide users with an all-round positive experience – no matter who they are or where they are located.
Bachem’s ethos, embodied in its strapline of ‘Leading Partner in Tides’ is of building strong partnerships with its stakeholders and is reflected across all the company’s activities, from initial contact through to successful project completion.
Since that collaboration invariably starts with a visit to the Bachem website, the project team wanted to ensure visitors found it easy to locate the information they needed and enjoyed an engaging experience from the very first click.
The first thing customers will notice is that the new website is a lot more interactive, offering enhanced ‘hover over’ and ‘click on’ expansion functions from menus. If accessing the site from a tablet or smartphone, they will also find the new site much more mobile-friendly.
The redesign also includes useful features like an interactive upcoming events calendar so customers can quickly and easily find an exhibition to meet one of Bachem’s sales representatives.
Bachem’s various business segments are more clearly and logically displayed, along with more direct access to support functions, ranging through projects in research, specialties, CMC development, commercialized APIs, or direct services and capabilities like project management, quality, analytics or manufacturing capabilities. For those seeking to progress a project involving peptide or oligonucleotide API production, the site makes it easier to identify those aspects where Bachem can help.
The new website also strengthens Bachem’s Knowledge Center containing valuable educational resources and tools, such as the Peptide Calculator, brand new Oligonucleotide Calculator, along with access to White Papers, presentations or technical notes.
Manuela Schneider, Bachem VP of Global Marketing, commented: “I would like to thank our fantastic team who put their time and energy to make this new website such a success.”
“Well over 100 different Bachem team members have been involved in this project, from writing content, to proofreading, creating graphics, development or release,” Ms. Schneider explained.
“It’s testament to a key part of our corporate culture at Bachem – passion and commitment – our employees make the difference,” she declared.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Under its banner Leading Partner in Tides, Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has five production sites in the US, UK and Switzerland along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, and new chemical entities (NCEs) at preclinical, clinical and production scales.
Further information at: www.bachem.com